‘…we must move with urgency to get it into the hands of the public where it can help bring an end to the pandemic…’
A clinical trial of a self administered nasal spray has been found to reduce SARS-CoV-2 viral load by more than 95% in infected patients within 24 hours of treatment, and by more than 99% within 72 hours.
The Nitric Oxide Nasal Spray (NONS), which has been developed by SaNOtize Research & Development Corp a biotech company based in Vancouver, British Columbia, Canada, was trialled at Ashford and St Peter’s Hospitals NHS Foundation Trust in Surrey, UK.
In a randomised, double-blind, placebo-controlled Phase 2 trial that evaluated 79 confirmed cases of covid-19, SaNOtize’s early treatment for Covid-19 significantly reduced the level of SARS-CoV-2. The majority of the cases involved people infected with the UK variant. No adverse health effects were recorded in the UK trial or from the 7000 self-administered treatments given earlier in Canadian clinical trials. The company is now applying to regulatory authorities in the UK and Canada for Emergency Use Authorisation.
The SaNOtize treatment is designed to kill SARS-CoV-2 in the upper airways, preventing it from incubating and spreading to the lungs. It is based on nitric oxide, a nanomolecule produced by the body with proven antimicrobial properties. The company said that the pharmacology, toxicity, and safety data for nitric oxide use in humans has been well established for decades.
SaNOtize Research & Development Corp said that NONs is the ‘only novel therapeutic treatment so far proven to reduce viral load in humans that is not a monoclonal antibody treatment. Monoclonal antibodies are highly specific, expensive and must be administered intravenously in a clinical setting.’
Dr Gilly Regev, CEO and co-founder of SaNOtize said; ‘Now that NONS has been demonstrated to be safe and effective in clinical trials, we must move with urgency to get it into the hands of the public where it can help bring an end to the pandemic, accelerate a return to normality and prevent future outbreaks of Covid-19 and its variants.’